Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672368 · ClinicalTrials.gov registry record · Phase 2
The da Vinci Single Port Robotic System for Use in Abdominal and Pelvic Surgical Procedures
A Phase 2 study of Disease or Disorder, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05672368: Recruiting Phase 2 study of Disease or Disorder, sponsored by City of Hope Medical Center.
NCT05672368 is a Phase 2 study of Disease or Disorder that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05672368, a Phase 2 study of Disease or Disorder, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial test the effectiveness and safety of a single-port robotic device (the da Vinci single port \[SP\]1098) for use in abdominal and pelvic surgeries. The da Vinci SP1098 robotic device can be used to perform less invasive surgeries that allow entry into the body through a single, small incision. The use of this device during surgery may allow surgeons to perform complex procedures that result in less pain, fewer complications and side effects, and improved recovery.
Primary Outcome
The number and frequency will be reported with 95% confidence intervals.
Conditions Studied
Interventions
- DEVICE Robot-Assisted Surgery
Study Locations (1)
California
- City of Hope Comprehensive Cancer Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-04-26 |
| Est. Completion | 2026-01-27 |
| Phase | Phase 2 |
What NCT05672368 shows while recruiting
NCT05672368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Disease or Disorder appearing as the primary indexed condition, and to 1 intervention - of which Robot-Assisted Surgery is the first listed.
NCT05672368 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05672368 about?
NCT05672368 is a clinical study titled "The da Vinci Single Port Robotic System for Use in Abdominal and Pelvic Surgical Procedures". This phase II trial test the effectiveness and safety of a single-port robotic device (the da Vinci single port \[SP\]1098) for use in abdominal and pelvic surgeries. The da Vinci SP1098 robotic device can be used to perform less invasive surgeries that allow entry into the body through a single, sm...
What is the current status of trial NCT05672368?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-04-26. Estimated completion is 2026-01-27.
What conditions does trial NCT05672368 study?
This clinical trial studies the following conditions: Disease or Disorder.
What interventions are being tested in trial NCT05672368?
The interventions under investigation include: Robot-Assisted Surgery (DEVICE).
Who is sponsoring clinical trial NCT05672368?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05672368 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05672368's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI